Compare TSSI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSSI | CSTL |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.5M | 661.7M |
| IPO Year | N/A | 2019 |
| Metric | TSSI | CSTL |
|---|---|---|
| Price | $8.63 | $38.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $38.67 |
| AVG Volume (30 Days) | ★ 2.2M | 439.7K |
| Earning Date | 11-13-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.63 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | $234,837,000.00 | ★ $343,530,000.00 |
| Revenue This Year | N/A | $1.69 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $45.78 | ★ N/A |
| Revenue Growth | ★ 91.66 | 10.15 |
| 52 Week Low | $5.63 | $14.59 |
| 52 Week High | $31.94 | $40.61 |
| Indicator | TSSI | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 33.57 | 71.92 |
| Support Level | $8.60 | $38.69 |
| Resistance Level | $9.48 | $40.54 |
| Average True Range (ATR) | 0.74 | 1.58 |
| MACD | 0.20 | -0.18 |
| Stochastic Oscillator | 53.05 | 75.59 |
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.